3Helix is an early-stage biotech company based on technology developed by a University of Utah group organized by Professior A MIchael Yu that was eraly on working on examining the principles of protein folding and assembly as they can be applied to develop new materials and biotechnologies, ranging from piezoelectric fibers to tissue engineering scaffolds and disease targeting molecules. One of those areas of investigation has been Collagen hybridization. Collagen has a unique triple helical structure that is unfolded in tissues during diseases, development, mechanical injury, and decellularization. established to develop and market a novel collagen targeting technology, providing scientists and clinicians with new tools to investigate collagen pathology and to develop diagnostics - the novel collagen targeting technology helps develop diagnostics and therapeutics for diseases with high collagen remodeling activities. 3Helix commercializes labeled collagen hybridizing peptide (CHP) that specifically binds to such unfolded collagen chains, enabling unlimited laboratory applications in pathology, biomechanics, cell biology, regenerative medicine, and more.
